



Article published on August 8th 2012 | [Fitness](#)

StemCyte India Therapeutics Pvt. Ltd. (SCITPL), is a joint venture company between StemCyte Inc. (USA), Apollo Hospitals Enterprises Ltd. and Cadila Pharmaceuticals Pvt. Ltd. into Collection, Processing, Storage and Therapeutic Applications of Umbilical Cord Blood Stem Cells.

The company headquartered in Ahmedabad, Gujarat is one of its kind having hybrid model operating both Private (Family) as well as Public (Donor's) Banking.

First time in India, a stem cell company having a complete stem cell solution under one roof from Banking to Applications.

The barometer of success of the stem cell industry is not just in banking of the child's stem cells but in its therapeutic applications.

Over 75 blood related diseases are proven to be treated through Umbilical Cord Blood Stem Cells which includes Leukemia, Thalassemia, Sickle Cell Anemia, Immune Deficiency Disease etc.

Approximately 10% of the total major haemoglobinopathy patients of the world are born in India. Of this, β^2 -Thalassemia is the most prominent disorder in our country. Gujarat itself has approx. 17% of the children suffering from Thalassemia major.

SCITPL clearly understands the need for treatment of these patients, and hence had recently offered fellowship program in Taiwan to two prominent transplant physicians namely:

>> Dr. Uday Deotare " Sterling Hospital- Ahmedabad

>> Dr. Samir Melinker " Shayadri Hospital, Deenanath Mangeshkar Hospital- Pune

The fellowship program enabled these physicians to understand the protocols for using Unrelated Umbilical Cord Blood Stem Cells for transplantation. This program was undertaken by Chung Gung Memorial Hospital, under the guidance and expertise of Dr. Tang-Her Jiang (a pioneer in cord blood transplants in the world having over 90%

success rate for disease free survival for Thalassemia).

This program shall enable these physicians to perform successful Umbilical cord Blood Stem Cells Transplantations in India.

StemCyte India is also associated with SCINET (Spinal Cord Injury Network) India and shall provide highest quality umbilical cord blood stem cells under clinical trials for stroke and spinal cord injury patients. This program is expected to commence by the end of 2011 under the leadership of Dr. Wise Young- Rutgers University USA.

The revolution in stem cell industry in India has now begun with a promise for a bright and healthier future.

Article Source:

<http://www.articleside.com/fitness-articles/stemcyte-india-a-complete-stem-cell-solution.htm> - [Article Side](#)

[Dilien Jhoncn](#) - About Author:

StemCyte India Therapeutics Pvt. Ltd. (SCIPTL) is a joint venture between StemCyte Inc. (USA). We Provides exclusively on developing industry-leading UCB processing technologies and establishing the largest, most racially diverse, and highest quality public bank(DONOR BANK) of UCB stem cell products in the industry. we applied his knowledge and understanding to a wide variety of a [cells india](#) and a [stem cells india](#).

Article Keywords:

stem cells india ,stem cells india,stem cells banking in india,stem cell banking,stem cell therapy India

You can find more [free articles](#) on [Article Side](#). Sign up today and share your knowledge to the community! It is completely FREE!